Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy
- 420 Downloads
New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.
KeywordsPneumonia Pneumocystis Pneumocystis jirovecii Rituximab Systemic Systemic lupus erythematosus
- 4.Bonilla-Abadía F, Echeverri AF, Izquierdo JH, Cañas F, Cañas CA (2012) Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection. Case report Rheumatol 2012:923897Google Scholar
- 10.Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J (2012) Rituximab therapy for severe pediatric systemic lupus erythematosus. Zhongha Er Ke Za 50:697–704Google Scholar
- 15.Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T et al (2009) Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1818–1823PubMedCrossRefGoogle Scholar
- 16.Castagnola E, Dallorso S, Faraci M, Morreale G, Di Martino D et al (2003) Long-lasting hypogammaglobulinemia following rituximab administration for Epstein–Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 12:9–10PubMedCrossRefGoogle Scholar